Skip to main content Accessibility help
×
Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-24T17:09:05.112Z Has data issue: false hasContentIssue false

10 - Hormone therapy

from Part II - Hormonal changes

Published online by Cambridge University Press:  21 August 2009

Kathy Andolsek
Affiliation:
Duke University Medical Center, Durham, NC, USA
Jo Ann Rosenfeld
Affiliation:
The Johns Hopkins University
Get access

Summary

Case: a 51-year-old healthy woman presents to the office. She has two children, 24 and 21 years of age, both delivered by cesarean section for fetal distress. Following the second delivery, she had a bilateral tubal ligation for contraception. She has had no other medical conditions. She reports that her menses have changed over the past year, becoming shorter and lighter. She occasionally skips a period altogether. She reports hot flushes, palpitations, and some sleep disruption. She believes that the sleep disruption has led to fatigue and some mild cognitive changes, which are beginning to interfere with her work performance. She has no personal or family history of breast cancer, coronary artery disease, or thromboembolic disease. She does have a family history of osteoporosis. She is a non-smoker, drinks two beers weekly, and exercises inconsistently. Her best friend had been on hormone therapy but stopped with the recent news concerning adverse effects. She wants to know whether she should consider hormonal therapy for her hot flushes and sleeping difficulty or if there is anything “safer.”

Introduction

Hormone therapy (HT) is the combined use of estrogen and progestin (EPT), or estrogen alone (ET), by postmenopausal or perimenopausal women. The US Food and Drug Administration (FDA) Office of Drug Evaluation has recently substituted the term “hormone therapy” for “hormone replacement therapy” to highlight the fact that postmenopausal hormones are treatment for certain conditions, not a necessary replacement for hormones that decrease as part of the normal menopause.

Type
Chapter
Information
Women's Health in Mid-Life
A Primary Care Guide
, pp. 151 - 190
Publisher: Cambridge University Press
Print publication year: 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

National Heart, Lung, and Blood Institute, National Institutes of Health: www.nhlbi.nih.gov/health/women/pht_facts.htm
Women's Health Initiative (WHI) of the National Heart, Lung, and Blood Institute, National Institutes of Health: www.whi.org
WHI site at which publications regarding HT are linked (often full text references): http://www.whi.org/etc/pubs.asp
The Office on Women's Health, US Department of Health and Human Services: www.4women.gov/owh
North American Menopause Society: www.menopause.org
Postmenopausal women at increased risk for breast cancer can compare safety and efficacy of chemoprophylaxis (tamoxifen and raloxifene) in reducing the risk of the disease. Risk assessment tool at: www.cancer.gov/bcrisktool
Duke University site for women: www.thewomenshealthsite.org
National Osteoporosis Foundation: www.nof.org
Maternal and Child Health Bureau. Women's Health USA 2002. www.mchb.hrsa.gov/data/women.htm. Accessed February 4, 2003
Porter, M., Penney, G., Russell, D., Russell, E. and Templeton, A.A population based survey of women's experience in the menopause. Br. J. Obstet. Gynaecol. 1996; 103:1025–8CrossRefGoogle ScholarPubMed
Brett, K. M. and Madans, J. H.Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am. J. Epidemiol. 1997; 145:536–45CrossRefGoogle ScholarPubMed
Kreling, D., Mott, D., Widerholt, J., Lundy, J. and Levitt, L. Prescription Drug Trends: A Chartbook Update. Menlo Park, CA: Kaiser Family Foundation; 2001
Utian, W. and Boggs, P.The North American Menopause Society 1998 menopause survey, part I: postmenopausal women's perceptions about menopause and midlife. Menopause 1998; 6:122–8Google Scholar
US Preventive Services Task Force. Recommendations and rationale: hormone replacement therapy for primary prevention of chronic conditions. www.ahcpr.gov/clinic/3rduspstf/hrt/hrtrr.htm. Accessed September 3, 2003
McNagny, S. E. and Jacobson, T. A.Use of postmenopausal hormone replacement therapy by African American women. The importance of physician discussion. Arch. Intern. Med. 1997; 157:1337–42CrossRefGoogle ScholarPubMed
Grodstein, F., Manson, J. E., Colditz, G. A., et al.A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular diseases. Am. Intern. Med. 2000; 133:933–41CrossRefGoogle Scholar
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M. and Allan, J. D.Postmenopausal hormone replacement therapy. Scientific review. J. Am. Med. Assoc. 2002; 288:872–81CrossRefGoogle ScholarPubMed
Hulley, S., Grady, D., Bush, T., et al.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 1998; 280:605–13CrossRefGoogle ScholarPubMed
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 2002; 288:321–33CrossRef
Voekler, R.Questions about hormone therapy remain puzzling. J. Am. Med. Assoc. 2002; 288:2395–6Google Scholar
Nelson, H. D., Humphrey, L. L., Le Blanc, E., et al. Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions. Summary of the Evidence. http://ahrq.gov/clinic/3rduspstf/hrt/hrtusum1.htm. Accessed August 21, 2002
Lemaitre, R. N., Heckbert, S. R., Psaty, B. M., Smith, N. L., Kaplan, R. C. and Longstreth, W. T.Hormone replacement therapy and associated risk of stroke in postmenopausal women. Arch. Intern. Med. 2002; 162:1954–60CrossRefGoogle ScholarPubMed
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 2002; 288:321–33CrossRef
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350:1047–59CrossRef
Hulley, S., Furberg, C., Barrett-Connor, E., et al. for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study Follow up HERS II. J. Am. Med. Assoc. 2002; 288:58–66CrossRef
Nelson, H. D., Humphrey, L. L., LeBlanc, E., et al. Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions. Summary of the Evidence. http://ahrq.gov/clinic/3rdusptf/hrt/hrtsum1.htm. Accessed August 18, 2002
Schairer, C., Lubin, J., Troisi, R., et al.Menopausal estrogen and estrogen progestin replacement therapy and breast cancer risk. J. Am. Med. Assoc. 2000; 283: 485–9CrossRefGoogle ScholarPubMed
Schairer, C., Lubin, J., Troisi, R., et al.Menopausal estrogen and estrogen progestin replacement therapy and breast cancer risk. J. Am. Med. Assoc. 2000; 283:485–9. [Erratum in J. Am. Med. Assoc. 2000; 284:2597.]CrossRefGoogle ScholarPubMed
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 2002; 288:321–33CrossRef
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350:1047–59CrossRef
Colditz, G., Hankinson, S., Hunter, D., et al.The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995; 332:1589–93CrossRefGoogle ScholarPubMed
Humphrey, L. L. Hormone replacement therapy and breast cancer. Systematic Evidence Review no. 14. www.ahrq.gov/clinic/serfiles.htm. Accessed January 14, 2003
Ettinger, B., Friedman, G., Bush, T. and Quesenberry, C. Jr.Reduced mortality associated with long term postmenopausal estrogen therapy. Obstet. Gynecol. 1996; 87:6–12CrossRefGoogle ScholarPubMed
Nanda, K., Bastian, L. A. and Schulz, K.Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am. J. Obstet. Gynecol. 2002; 186:325–34CrossRefGoogle ScholarPubMed
Beresford, S., Weiss, N., Voigt, L., et al.Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349:458–61CrossRefGoogle ScholarPubMed
Pike, M. C., Peters, R. K., Cozen, W., et al.Estrogen progestin replacement and endometrial cancer. J. Natl Cancer Inst. 1997; 89:1110–16CrossRefGoogle ScholarPubMed
Nelson, H. D., Humphrey, L. L., LeBlanc, E., et al. Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions. Summary of the Evidence. http://ahrq.gov/clinic/3rduspstf/hrt/hrtsum1.htm. Accessed August 21, 2002
Lacey, J. V. Jr, Mink, P. J., Lubin, J. H., et al.Menopausal hormone replacement therapy and risk of ovarian cancer. J. Am. Med. Assoc. 2002: 288:334–41CrossRefGoogle ScholarPubMed
Rodriguez, C., Patel, A. V., Calle, E. E., et al.Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J. Am. Med. Assoc. 2001; 285:14CrossRefGoogle Scholar
Weiss, N. S. and Rossing, M. A.Oestrogen replacement therapy and risks of ovarian cancer. Lancet 2001; 358:438CrossRefGoogle ScholarPubMed
Riman, T., Dickman, P. W., Nilsson, S., et al.Hormone replacement therapy and the risk of invasive ovarian cancer in Swedish women. J. Natl Cancer Inst. 2002; 94:497–504CrossRefGoogle ScholarPubMed
Henderson, W. V., Kelin, B. E. K. and Resnick, S. M. Menopause and disorders of neurologic function, mental health and the eye. In Wenger, N. K., Paoletti, R., Lenfant, C. I. M. and Pinn, V. W. (eds.). International Position Paper on Women's Health and Menopause: A Comprehensive Approach, vol 02-3284. Bethesda, MD: National Institutes of Health; 2002. pp. 251–70
Novartis Foundation. Neuronal and cognitive effects of oestrogens. Monograph no. 230. Chicester, UK: John Wiley & Sons; 2002
Yaffe, K., Sawaya, G., Lieberburg, I. and Gradey, D.Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J. Am. Med. Assoc. 1998; 279:688–95CrossRefGoogle ScholarPubMed
LeBlanc, E. S., Janowsky, J., Chan, B. K. and Nelson, H. D.Hormone replacement therapy and cognition: systematic review and meta-analysis. J. Am. Med. Assoc. 2001; 285:1489–99CrossRefGoogle ScholarPubMed
Fillit, H. M.The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch. Intern. Med. 2002; 162:1934–42CrossRefGoogle ScholarPubMed
Seshadri, S., Zornberg, F. L., Derby, L. E., et al.Postmenopausal estrogen replacement therapy and the risk of AD. Arch. Neurol. 2001; 58:435–40CrossRefGoogle Scholar
Zandi, P. P., Carlson, M. C., Plassman, B. L., et al.Hormone replacement therapy and incidence of Alzheimer disease in older women. The Cache County Study. J. Am. Med. Assoc. 2002; 288:2123–9CrossRefGoogle ScholarPubMed
Hlatky, M. A., Boothroyd, D., Vittinghoff, E., et al.Quality of life and depressive symptoms in postmenoapusal women after receiving hormone therapy. J. Am. Med. Assoc. 2002; 287:591–7CrossRefGoogle Scholar
White, C.Second long term HRT trial stopped early. Br. Med. J. 2002; 325:987CrossRefGoogle ScholarPubMed
Asthana, S., Baker, L. D., Craft, S., et al.High dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001; 57: 605–12CrossRefGoogle ScholarPubMed
Cholerton, B., Gleason, C. E., Baker, L. D. and Asthana, S.Estrogen and Alzheimer's disease: the story so far. Drugs Aging 2002; 19:405–27CrossRefGoogle ScholarPubMed
Kanaya, A. M., Herrington, D., Vittinghoff, E., et al.Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study. A randomized double-blind, placebo-controlled trial. Am. Intern. Med. 2003; 138:1–9CrossRefGoogle Scholar
Grodstein, F., Colditz, G. A. and Stampfer, M. J.Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet. Gynecol. 1994; 83:5–11Google Scholar
Barbabei, V. M., Grady, D., Stovall, D. W., et al.Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet. Gynecol. 2002; 100:1209–18Google Scholar
Grady, D., Herrington, D., Bittner, V., et al.for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). J. Am. Med. Assoc. 2002; 288:49–57CrossRefGoogle Scholar
American Heart Association. Estrogen and Cardiovascular Disease in Women. http://www.americanheart.org/presenter.jhtml?identifier=4536. Accessed January 12, 2003
American College of Obstetricians and Gynecologists. Questions and Answers on Hormone Therapy. http://www.acog.org/from_home/publications/press_releases/nr08-30-02.cfm
North American Menopause Society. Amended report from the NAMS Advisory Panel on Postmenopausal hormone therapy. Menopause 2003; 10:6–12CrossRef
US Preventive Services Task Force. Hormone replacement therapy for primary prevention of chronic conditions. http://www.ahcpr.gov/clinic/3rduspstf/hrt/hrtrr.htm
Voelker, R.Questions about hormone therapy remain puzzling. J. Am. Med. Assoc. 2000; 288:2395–6CrossRefGoogle Scholar
Hlatky, M. A., Boothroyd, D., Vittinghoff, E., et al.Heart and Estrogen Progestin Replacement Study Research Group. Quality of life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen Progestin Replacement Study Trial. J. Am. Med. Assoc. 2002; 287:591–6CrossRefGoogle Scholar
Soloman, C. G. and Dhluly, R. G.Rethinking postmenopausal hormone therapy. N. Engl. J. Med. 2002; 348:579–80CrossRefGoogle Scholar
Voelker, R.Questions about hormone therapy remain puzzling. J. Am. Med. Assoc. 2000; 288:2395–6CrossRefGoogle Scholar
Greendale, G. A., Espeland, M., Slone, S., Marcus, R. and Barrett-Connor, E.Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety follow-up study. Arch. Intern. Med. 2002; 162:665–72CrossRefGoogle ScholarPubMed
Gallagher, J. C., Rapuri, P. B., Haynatzki, G. and Detter, J. R.Effect of discontinuation of estrogen, calcitrol, and the combination of both on bone density and bone markers. J. Clin. Endocrinol. Metab. 2002; 87:4914–23CrossRefGoogle Scholar
New Zealand Guidelines Group. Best practice evidence-based guideline for the appropriate prescribing of hormone replacement therapy. www.guidelines.gov. September 2002
Ansbacker, R.The pharmacokinetics and efficacy of different estrogens are not equivalent. Am. J. Obstet. Gynecol. 2001; 184:255–63CrossRefGoogle Scholar
Eriksen, B.A randomized open parallel-group study on the preventive effects of an estradiol-releasing vaginal ring on current urinary tract infections in postmenopausal women. Am. J. Obstet. Gynecol. 1999; 180:1072–9CrossRefGoogle Scholar
US Food and Drug Administration. FDA approves new labels for estrogen and estrogen with progestin therapies for postmenopausal women following review of women's health initiative data. http://www.fda.gov/bbs/topics/NEWS/2003/NEW00863.html. Accessed January 9, 2003
American College of Obstetricians and Gynecologists. Use of botanicals for management of menopausal symptoms. Clinical Management Guidelines for Obstetrician-Gynecologists. ACOG Practice Bulletin No. 28, June 2001. www.acog.org/from_home/publications/misc/pb028.htm
Nelson, H. D.Assessing benefits and harms of hormone replacement therapy clinical applications. J. Am. Med. Assoc. 2002; 288:882–4CrossRefGoogle ScholarPubMed
Leonetti, H. B., Longo, S. and Anasti, J. N.Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet. Gynecol. 1999; 94:225–8Google ScholarPubMed
Moore, R. A.Livial: a review of clinical studies. Br. J. Obstet. Gynaecol. 1999; 106(supp 19):1–21Google ScholarPubMed
Faure, E. D., Chantre, P. and Mares, P.Effects of a standardized soy extract on hot flushes: a multicenter, double blind randomized placebo controlled study. Menopause 2002; 9:329–34CrossRefGoogle ScholarPubMed
Han, K. K., Soares, J. M., Haidar, M. A., Lima, G. R. and Baracat, E. C.Benefits of soy isoflavones therapeutic regimen on menopausal symptoms. Obstet. Gynecol. 2002; 99:389–94Google ScholarPubMed
Hughes, C. Easing menopausal symptoms with soy. http://dukehealth.org/news/healthtip_october02.asp. Accessed November 4, 2002
Liske, E., Hanggi, W., Henneicke-von Zepelin, H. H., Boblitz, N., Wustenberg, P. and Rahlfs, V. W.Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J. Womens Health Gend Based Med. 2002; 11:163–74CrossRefGoogle ScholarPubMed
American College of Obstetricians and Gynecologists. Use of botanicals for management of menopausal symptoms. Clinical Management Guidelines for Obstetrician–Gynecologists. ACOG Practice Bulletin No. 28, June 2001. www.acog.org/from_home/publications/misc/pb028.htm. Accessed December 14, 2002
Office of Dietary Supplements, National Institutes of Health. Questions and answers about black cohosh and the symptoms of menopause. http://ods.od.nih.gov/factsheets/blackcohosh.html
Office of Dietary Supplements NIH/The National Center for Complementary and Alternative Medicine at the NIH. Dietary supplements, complementary or alternative medicines. www.nlm.nih.gov/services/dietsup.html
American College of Obstetricians and Gynecologists. Use of botanicals for management of menopausal symptoms. Clinical Management Guidelines for Obstetrician–Gynecologists. ACOG Practice Bulletin No. 28, June 2001. www.acog.org/from_home/publications/misc/pb028.htm. Accessed January 7, 2003
Rious, J. E., Devlin, C., Gelfant, M. M., et al.17 beta estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000; 7:140–42Google Scholar
Grady, D.A 60 year old woman trying to discontinue hormone replacement therapy. J. Am. Med. Assoc. 2002; 287:2130–37CrossRefGoogle ScholarPubMed
Nelson, H. D.Assessing benefits and harms of HRT: clinical applications. J. Am. Med. Assoc. 2002; 288:882–4CrossRefGoogle ScholarPubMed
US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Am. Fam. Physician 2002; 66:1430–32
US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Am. Intern. Med. 2002; 137:526–8CrossRef
Greendale, G. A., Espeland, M., Slone, S., Marcus, R. and Barrett-Connor, E.Bone mass response to discontinuation of long-term hormone replacement therapy. Arch. Intern. Med. 2002; 162:665–72CrossRefGoogle ScholarPubMed
Davis, S. R.Androgens and female sexuality. J. Gend. Specif. Med. 2000; 3:36–40Google ScholarPubMed
Solomon, C. G. and Dluhy, R. G.Rethinking postmenopausal hormone therapy. N. Engl. J. Med. 2003; 348:579–81CrossRefGoogle ScholarPubMed
Grodstein, F., Clarkson, T. B. and Manson, J. E.Understanding the divergent data on postmenopausal hormone therapy. N. Engl. J. Med. 2003; 348:645–50.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Hormone therapy
  • Edited by Jo Ann Rosenfeld, The Johns Hopkins University
  • Book: Women's Health in Mid-Life
  • Online publication: 21 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545672.010
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Hormone therapy
  • Edited by Jo Ann Rosenfeld, The Johns Hopkins University
  • Book: Women's Health in Mid-Life
  • Online publication: 21 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545672.010
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Hormone therapy
  • Edited by Jo Ann Rosenfeld, The Johns Hopkins University
  • Book: Women's Health in Mid-Life
  • Online publication: 21 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545672.010
Available formats
×